Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated (Nasdaq: CYTK) is a specialty cardiovascular biopharmaceutical company that regularly issues news about its medicines and programs in cardiac muscle dysfunction. Company updates frequently highlight MYQORZO (aficamten), a cardiac myosin inhibitor that Cytokinetics reports is approved in the United States and China for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms, as well as related regulatory developments in other regions.
News for CYTK often covers key regulatory milestones such as positive opinions from the Committee for Medicinal Products for Human Use of the European Medicines Agency, approvals by national regulatory agencies and progress of New Drug Application reviews. Cytokinetics also reports on clinical trial data from studies like SEQUOIA-HCM and MAPLE-HCM, including results presented at major cardiology congresses and publications in peer-reviewed journals.
Investors and observers can find announcements about the company’s broader pipeline, including omecamtiv mecarbil in heart failure with severely reduced ejection fraction, ulacamten in heart failure with preserved ejection fraction and CK-089 in skeletal muscle disorders. Additional news items describe financial results, capital raising activities, inducement equity grants, executive appointments and participation in healthcare and investor conferences.
This CYTK news page aggregates these disclosures so readers can follow developments in Cytokinetics’ cardiovascular programs, regulatory interactions and corporate activities over time.
Cytokinetics (Nasdaq: CYTK) and Ji Xing Pharmaceuticals have expanded their collaboration to develop omecamtiv mecarbil for heart failure treatment in Greater China. Cytokinetics will receive $70 million in committed capital, including $50 million from Ji Xing and $20 million from RTW Investments through common stock sales. Additionally, Cytokinetics could earn up to $330 million in milestone payments and royalties. This partnership aims to enhance patient access to innovative therapies for heart failure in a significant cardiovascular market.
Cytokinetics announced significant findings regarding the ongoing Phase 3 clinical trial, COURAGE-ALS, for reldesemtiv in ALS patients. Data presented at the 32nd International Symposium on ALS/MND revealed that a majority (85.2%) of the initial 27 enrolled patients exhibit either middle (48.2%) or fast (37.0%) disease progression rates. This targeted enrollment aims to enhance the detection of treatment effects, as evidenced by previous studies. Furthermore, supplemental analyses from FORTITUDE-ALS highlighted key correlations between grip strength and patient-reported quality of life.
FDA Grants Breakthrough Therapy Designation for aficamten, developed by Cytokinetics, targeting symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This designation accelerates the drug's development, indicating potential for significant improvement over existing treatments. Preliminary results from the REDWOOD-HCM Phase 2 trial showed that aficamten effectively reduced left ventricular outflow tract pressure gradients and improved heart failure symptoms. Cytokinetics is advancing to SEQUOIA-HCM, a Phase 3 trial, following these promising outcomes.
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the grant of stock options for 143,500 shares to 9 new employees as a material inducement for their employment, effective November 30, 2021. The exercise price is set at $39.34 per share, aligned with the closing stock price on that date. The options will vest over four years, with a quarter vesting on the one-year anniversary and the remainder monthly thereafter. This action is compliant with Nasdaq Listing Rule 5635(c)(4). Cytokinetics continues to focus on muscle performance treatments, including ongoing clinical trials for its drug candidates.
Cytokinetics (Nasdaq: CYTK) announced its participation in the 32nd International Symposium on ALS/MND from December 7-10, 2021, featuring one oral and three poster presentations. The oral presentation will cover a European survey on ALS, while the posters will discuss various clinical trials, including Phase 2 and Phase 3 studies of Reldesemtiv and its impact on ALS patients. The company continues to advance its innovative therapies aimed at enhancing muscle function, including omecamtiv mecarbil and aficamten, with ongoing Phase 3 trials.
Cytokinetics (Nasdaq: CYTK) announced that CEO Robert I. Blum will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, 2021. The chat will be pre-recorded and available for on-demand viewing starting November 22, 2021, at 10:00 AM ET. It can be accessed through the Investors & Media section of Cytokinetics' website. The company focuses on innovative muscle activators and inhibitors to treat diseases affecting muscle performance, with ongoing Phase 3 trials for its candidates.
Cytokinetics announced significant results from the GALACTIC-HF trial, revealing that treatment with omecamtiv mecarbil substantially reduces stroke risk in patients with heart failure with reduced ejection fraction (HFrEF). Specifically, the risk of fatal/non-fatal strokes decreased by 35%, with a notable 77% reduction for patients with a history of stroke. Preclinical data on CK-136 demonstrated potential for enhancing cardiac contractility without affecting efficiency. These findings may influence future treatments for heart failure, positioning Cytokinetics favorably.
Cytokinetics (CYTK) announced two presentations at the American Heart Association Scientific Sessions 2021 from Nov 13-15. One presentation will discuss the effects of omecamtiv mecarbil on stroke in heart failure patients with reduced ejection fraction, while another will showcase a novel small molecule troponin activator's impact on cardiac function. Cytokinetics is also progressing towards a U.S. NDA submission for omecamtiv mecarbil following positive results from the GALACTIC-HF trial and is advancing its clinical trials for other cardiac treatments.
Cytokinetics reported a net loss of $76.1 million, or $0.95 per share, for Q3 2021, significantly higher than a $3.2 million loss in Q3 2020. Cash and investments stand at $668.9 million. Key milestones include plans for a New Drug Application for omecamtiv mecarbil by Q4 2021 and successful results from REDWOOD-HCM. The company reported a decline in revenue to $5.4 million for Q3 2021, down from $41.7 million in the same period last year, primarily due to the absence of licensing revenue. R&D expenses increased to $48.4 million in Q3.
Cytokinetics (Nasdaq: CYTK) announced on October 29, 2021, the grant of stock options to 8 new employees, totaling 68,550 shares, as a material inducement for their employment. The exercise price for these options is set at $34.91 per share, aligning with the closing stock price on the grant date. Shares will vest over four years, with a quarter vesting after one year and the rest monthly thereafter. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to strengthen the company's workforce.